Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its second quarter 2017 financial results after the close of market on Monday, July 31, 2017. Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and business progress.

The live webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Alternatively, please call (855) 541-0980 (U.S.) or (970) 315-0440 (international) to listen to the live conference call. The conference ID number is 44718214. The webcast replay will be available on the company's website approximately two hours following completion of the call and archived on the company's website for 90 days.

About Veracyte

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170718005783/en/

Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
[email protected]
or
Investors:
Jackie Cossmon, 650-243-6371
[email protected]

Source: Veracyte, Inc.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Oceanfirst Financial (OCFC) Tops Q1 EPS by 3c
• Veracyte, Inc (VCYT) PT Lowered to $28 at Goldman Sachs